Artemis Medicare Services Ltd is Rated Buy

Current Rating and Its Significance

MarketsMOJO’s 'Buy' rating for Artemis Medicare Services Ltd indicates a favourable investment stance based on a thorough evaluation of multiple key parameters. The rating was adjusted on 08 Dec 2025, when the company’s Mojo Score improved significantly from 54 to 70, signalling enhanced confidence in the stock’s prospects. Investors should understand that this rating reflects a recommendation to consider accumulating shares, supported by the company’s current financial health, valuation, and market trends.

Quality Assessment

As of 25 January 2026, Artemis Medicare Services Ltd holds an average quality grade. This assessment considers the company’s operational consistency, profitability, and ability to sustain growth. Notably, the company has demonstrated a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.34 times, which suggests prudent financial management and reduced risk of over-leverage. Furthermore, Artemis has declared positive results for seven consecutive quarters, underscoring stable earnings momentum.

Valuation Perspective

The valuation grade for Artemis Medicare Services Ltd is currently attractive. The stock trades at a Price to Book Value of 4.1, which is considered reasonable relative to its sector peers and historical averages. Despite the stock’s one-year return being negative at -27.23%, the company’s profits have grown by 46.9% over the same period, resulting in a PEG ratio of 1.4. This indicates that the stock’s price is not excessively high compared to its earnings growth, offering a compelling entry point for value-conscious investors.

Financial Trend Analysis

The financial trend for Artemis Medicare Services Ltd is very positive. The latest data shows an impressive annual growth rate of 82.15% in operating profit, reflecting robust operational expansion. Net profit growth stands at 41.51%, reinforcing the company’s improving profitability. Additionally, the company’s operating cash flow for the year reached a peak of ₹139.08 crores, and its Return on Capital Employed (ROCE) for the half-year is at a healthy 13.34%. The debt-equity ratio remains low at 0.32 times, further highlighting the company’s strong balance sheet and capacity to fund growth without excessive borrowing.

Technical Outlook

From a technical standpoint, Artemis Medicare Services Ltd is mildly bullish. While the stock has experienced short-term price declines—down 1.8% on the latest trading day and 16.61% year-to-date—the underlying momentum suggests potential for recovery. The mild bullish technical grade indicates that the stock may be consolidating before a possible upward move, making it an interesting candidate for investors who monitor price trends alongside fundamentals.

Stock Performance Overview

As of 25 January 2026, the stock’s performance has been mixed. The one-day decline of 1.8% and a one-month drop of 17.68% reflect recent volatility. Over the past year, the stock has declined by 27.23%, which contrasts with the company’s strong profit growth. This divergence suggests that the market may not have fully priced in the company’s improving fundamentals, potentially creating an opportunity for investors who focus on long-term value.

Implications for Investors

The 'Buy' rating from MarketsMOJO signals that Artemis Medicare Services Ltd is currently viewed as a stock with favourable risk-reward characteristics. Investors should consider the company’s solid financial trends, attractive valuation, and improving operational quality when making portfolio decisions. The rating implies confidence in the company’s ability to generate sustainable returns over time, despite recent price fluctuations.

Sector and Market Context

Artemis Medicare Services Ltd operates within the hospital sector, a segment that has shown resilience and growth potential amid evolving healthcare demands. As a small-cap company, Artemis faces both opportunities and challenges typical of its market capitalisation, including higher volatility but also greater growth prospects. The company’s improving fundamentals and attractive valuation position it well relative to peers, especially in a sector where quality healthcare delivery and operational efficiency are increasingly valued by investors.

Conclusion

In summary, Artemis Medicare Services Ltd’s current 'Buy' rating by MarketsMOJO reflects a comprehensive assessment of its quality, valuation, financial trends, and technical outlook as of 25 January 2026. The company’s strong profit growth, prudent debt management, and attractive valuation metrics underpin this positive stance. While the stock has experienced recent price declines, the underlying fundamentals suggest a favourable investment opportunity for those seeking exposure to the hospital sector’s growth potential. Investors should weigh these factors carefully within their broader portfolio strategy and risk tolerance.

Unlock special upgrade rates for a limited period. Start Saving Now →